Cargando…

Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation

We aimed to develop a pharmacokinetic (PK) and pharmacodynamic (PD) model from healthy Chinese subjects and real-world non-valvular atrial fibrillation (NVAF) patients. We also investigated meaningful intrinsic and extrinsic factors and related biomarkers for bleeding events. We characterized the in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ya-ou, Xie, Qiu-fen, Liu, Zhi-yan, Wang, Zhe, Mu, Guang-yan, Zhang, Ya-tong, Zhao, Zi-nan, Yuan, Dong-dong, Guo, Li-ping, Wang, Na, Xiang, Jing, Song, Hong-tao, Jiang, Jie, Xiang, Qian, Cui, Yi-min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650305/ https://www.ncbi.nlm.nih.gov/pubmed/36386303 http://dx.doi.org/10.3389/fcvm.2022.998751

Ejemplares similares

Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
por: Huber, K, et al.
Publicado: (2013)

FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation
por: J, Aalbers, et al.
Publicado: (2010)

Anticoagulation efficacy of dabigatran etexilate for left atrial appendage thrombus in patients with atrial fibrillation by transthoracic and transesophageal echocardiography
por: Xing, Xiao Fei, et al.
Publicado: (2018)

Dabigatran etexilate tetrahydrate
por: Liu, Hong-Qiang, et al.
Publicado: (2012)

The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients
por: Ellis, Christopher R, et al.
Publicado: (2013)

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
por: Pink, Joshua, et al.
Publicado: (2011)

The Discovery of Dabigatran Etexilate
por: van Ryn, Joanne, et al.
Publicado: (2013)

Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation
por: Simpson, Bryan H., et al.
Publicado: (2019)

Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling
por: Wang, Nan, et al.
Publicado: (2020)

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
por: Kansal, Anuraag R, et al.
Publicado: (2012)

Choice of Renal Function Estimator Influences Adverse Outcomes with Dabigatran Etexilate in Patients with Atrial Fibrillation
por: Simpson, Bryan H., et al.
Publicado: (2018)

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile
por: Clemens, Andreas, et al.
Publicado: (2012)

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
por: Härtter, Sebastian, et al.
Publicado: (2012)

New options with dabigatran etexilate in anticoagulant therapy
por: Maegdefessel, Lars, et al.
Publicado: (2010)

Dabigatran-etexilate: Lack of efficacy: case report
Publicado: (2021)

Recovery of Visual Function after Administration of Dabigatran Etexilate
por: Schönfeld, Carl-Ludwig, et al.
Publicado: (2014)

Dabigatran etexilate: Cholestatic liver injury: case report
Publicado: (2021)

Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects
por: Duan, Jingli, et al.
Publicado: (2020)

Physiologically‐based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate
por: Farhan, Nashid, et al.
Publicado: (2021)

A Study of Cardiogenic Stroke Risk in Non-valvular Atrial Fibrillation Patients
por: Song, Ziliang, et al.
Publicado: (2020)

The effects of dabigatran etexilate on fracture healing in rats: An experimental study
por: Kerimoglu, Servet, et al.
Publicado: (2015)

Hemopericardium and Cardiac Tamponade in a Patient Treated with Dabigatran Etexilate
por: Kızılırmak, Filiz, et al.
Publicado: (2016)

Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults
por: Sia, Jie En Valerie, et al.
Publicado: (2023)

Pharmacokinetic modeling and simulation support for age‐ and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism
por: Röshammar, Daniel, et al.
Publicado: (2021)

Preliminary Observations on the Antihypertension Action of Dabigatran Etexilate in Patients With Nonvalvular Atrial Fibrillation: A Prospective Multicenter Single-Arm Interventional Study
por: Yamamoto, Tomohiko, et al.
Publicado: (2020)

Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin
por: Fonseca, Eileen, et al.
Publicado: (2015)

Rhabdomyolysis happened after the start of dabigatran etexilate treatment: A case report
por: Zheng, Tingting, et al.
Publicado: (2022)

The value of left atrial longitudinal strain in evaluating left atrial appendage spontaneous echo contrast in non-valvular atrial fibrillation
por: Ma, Chang sheng, et al.
Publicado: (2023)

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study
por: Sørensen, Rikke, et al.
Publicado: (2013)

Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran: a real-world study
por: Zhou, Wei, et al.
Publicado: (2019)

Dabigatran for left atrial thrombus
por: Morita, Sae, et al.
Publicado: (2013)

Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate
por: Bellamy, L, et al.
Publicado: (2009)

The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency
por: Gribkova, Irina V., et al.
Publicado: (2016)

Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial
por: Yoshida, Yukihiko, et al.
Publicado: (2018)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Bioequivalence and pharmacodynamics of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions
por: Li, Xin, et al.
Publicado: (2020)

Impact of Renal Function on Effectiveness and Safety Associated With Low Dose Dabigatran in Non-valve Atrial Fibrillation Patients After Catheter Ablation
por: Li, Xiaoye, et al.
Publicado: (2021)

Quantitative acetylated proteomics on left atrial appendage tissues revealed atrial energy metabolism and contraction status in patients with valvular heart disease with atrial fibrillation
por: Tu, Tao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jh9qcqc8n3n6kkmsav77dh0p9h